SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as investors await a key decision from the EMA regarding its Alzheimer's drug, Blarcamesine, with an oral explanation scheduled. The community is actively discussing the implications of this oral explanation, analyzing potential outcomes and comparing Blarcamesine to existing treatments. Some traders express concerns about potential short attacks and are attempting to decipher the impact of an oral explanation.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

GLTO is trending as traders discuss its potential for another run, fueled by a small float and high volatility. Community members are debating entry points, profit-taking strategies, and the possibility of a short squeeze. Some are comparing it to other recent high-flying stocks with similar setups.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending amid discussions around its potential acquisition of Northern Data and its implications for GPU capacity and AI capabilities. Community members are weighing the potential for a short squeeze, given the high short interest and the involvement of figures like Tether and the Trump team. Some express frustration with the stock's performance and leadership, while others remain optimistic about Rumble's long-term prospects in the media and cloud space.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

OSCR is trending downwards as investors react to potential changes in ACA subsidies and broader sector headwinds affecting healthcare stocks. The community is actively debating the impact of these changes on Oscar Health's business model, with some seeing it as a buying opportunity due to long-term growth potential and oversold conditions, while others express concerns about profitability and ACA reliance. Traders are closely monitoring key support levels and awaiting further news on government actions regarding healthcare.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano (MOVE) is trending due to news of Nasdaq granting an extension to regain listing compliance, sparking significant community interest and heavy trading volume. Community discussions revolve around potential price targets and whether the stock can sustain its upward momentum, with some anticipating a squeeze. The stock's low float and history of volatility are also contributing to the heightened attention.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind's stock is trending downwards following news that its Phase 3 trial for nebulized clofazimine failed to demonstrate efficacy, leading the company to discontinue the trial and shift focus to a dry powder version. The community is expressing disappointment with the company's leadership and questioning the future of the stock, with some speculating about a potential acquisition. Investors are discussing the implications for future earnings and expressing concern about the company's pipeline and strategic decisions.

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Galectin Therapeutics Inc

$GALT is trending due to growing excitement surrounding presentations at the AASLD Liver Meeting in November, where Belapectin's potential in treating MASH cirrhosis will be highlighted. The community is actively discussing the possibility of a buyout or partnership, particularly with companies seeking to enhance their GLP-1 portfolios, and speculating on a potential short squeeze fueled by high short interest.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending following impressive Q3 results, including exceeding EPS and revenue expectations, which has sparked a surge in pre-market trading. The community is focused on the company's strong fundamentals, low float, and potential short squeeze, with many believing the stock is currently undervalued. Bullish sentiment is fueled by raised full-year guidance and comparisons to competitors, while some express concern over potential market volatility and historical price patterns.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is trending as investors debate the cause of recent price declines despite seemingly positive financial results, with community members pointing to competition from Roche and potential profit-taking as factors. Discussion revolves around whether the company will be acquired, if a buyback will occur, and the impact of insider share transfers. Bullish arguments center on Briumvi's market position and potential, while bears cite chart patterns and macro conditions.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending downwards, with community members expressing concerns about the company's performance relative to Bitcoin's price and overall faith in Michael Saylor's leadership; some traders believe the stock is oversold and due for a bounce, while others view it as a risky play. Discussions include perspectives on potential catalysts like a government shutdown resolution and index inclusion, but also debate around debt obligations and the sustainability of the business model.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Applied Optoelectronics (NASDAQ:AAOI) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Applied Optoelectronics (NASDAQ:AAOI - Get Free Report) issued its quarterly earnings data on Thursday. The semiconductor company reported ($0.09) EPS for the quarter, beating the consensus estimate...

Applied Optoelectronics (NASDAQ:AAOI) Shares Gap Down - Here's Why

Applied Optoelectronics (NASDAQ:AAOI) Shares Gap Down - Time to Sell...

Applied Optoelectronics (NASDAQ:AAOI) Releases Q4 2025 Earnings Guidance

Applied Optoelectronics (NASDAQ:AAOI) updated its fourth quarter 2025 earnings guidance. The company provided EPS guidance of -0.130--0.040 for the period. The company also issued revenue guidance of...

Why Applied Optoelectronics Stock Sank Today

Key PointsIt broadly met analyst estimates for revenue in its third quarter, but missed on the bottom line...

Applied Optoelectronics (AAOI) Reports Q3 Loss, Misses Revenue Estimates

Applied Optoelectronics (AAOI) delivered earnings and revenue surprises of +10.00% and -1.06%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for These 5 Semiconductor Stocks This Earnings Season?

Strong global chip sales set the stage for upbeat earnings from key semiconductor players, including LASR, AAOI, SYNA, NVMI and DIOD.

Lam Research Stock Trades at Low P/E: Should You Buy, Sell or Hold?

Despite robust growth in AI and HPC, LRCX faces near-term risks tied to China sales and chip cycle swings.

Applied Optoelectronics (AAOI) Reports Q2 Loss, Misses Revenue Estimates

Applied Optoelectronics (AAOI) delivered earnings and revenue surprises of -100.00% and -1.83%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

AXT (AXTI) Reports Q2 Loss, Beats Revenue Estimates

AXT (AXTI) delivered earnings and revenue surprises of -15.38% and +0.53%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Marvell (MRVL): Can Its 7.1% Jump Turn into More Strength?

Marvell (MRVL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.11	--	--	N/A
Q3 '25	-$0.09	-$0.09	2.16%	BEAT
Q2 '25	-$0.07	-$0.16	-123.99%	MISSED
Q1 '25	-$0.04	-$0.02	49.20%	BEAT
Q4 '24	-$0.02	-$0.02	-10.50%	MISSED

AAOI
Applied Optoelectronics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest AAOI News

AAOIApplied Optoelectronics Inc